Brii Biosciences Ltd. is a biotechnology company dedicated to developing innovative therapies that target significant infectious diseases and central nervous system conditions. Established in 2017 and headquartered in Beijing, China, the company is recognized for its broad pipeline of proprietary drug candidates, particularly addressing major health burdens such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), and multi-drug resistant bacterial infections. Notable products in its HBV portfolio include a therapeutic vaccine and advanced therapeutic agents like siRNA-based and antibody treatments. Brii Biosciences also invests in research for therapies addressing drug-resistant infections and central nervous system disorders. Its primary operations and market focus are in China, where it seeks to mitigate public health challenges through scientific innovation and strategic partnerships. The company’s emphasis on unmet medical needs underscores its role as a key contributor in the biotechnology and medical research sectors.